https://investor.ironwoodpharma.com/generated by Q4Mon, 06 Apr 2026 16:52:35 -0400Copyright Q4 Inc. All rights reserved.3ddf1106-f052-4d6d-a65a-e3135c435bfbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspxWed, 04 Mar 2026 16:05:00 -05002371ea25-d761-4c21-ae7c-18c04691212fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Achieves-2025-Financial-Guidance-and-Reiterates-Strong-2026-Outlook/default.aspxWed, 25 Feb 2026 07:05:00 -05009408b00f-4072-49f6-a48d-ed83283f469ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2025-Investor-Update-Call/default.aspxWed, 18 Feb 2026 16:21:00 -05005c92fea9-9dac-40e2-8839-a73ed1386a15https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Maintains-FY-2025-Financial-Guidance-and-Announces-FY-2026-Financial-Guidance/default.aspxFri, 02 Jan 2026 07:05:00 -050075c71f11-f67c-4dc6-8156-5cdd7b87f9a5https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2025-Results-Raises-Full-Year-2025-Financial-Guidance/default.aspxMon, 10 Nov 2025 07:05:00 -05001d3083f8-327b-4633-b2d0-02907cdc013chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2025-Results-Maintains-Full-Year-2025-Financial-Guidance/default.aspxThu, 07 Aug 2025 07:05:00 -040029557cea-91a1-451f-bf36-ab9e1c27d353https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-First-Quarter-2025-Results/default.aspxWed, 07 May 2025 07:05:00 -0400e6231a65-541d-4241-a4fd-8d1d1b769f5ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspxWed, 30 Apr 2025 16:25:00 -04008aed17c5-de59-4dca-8704-97551ae95d29https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reiterates-Full-Year-2025-LINZESS-U-S--Net-Sales-Guidance-and-Raises-Adjusted-EBITDA-Guidance/default.aspxFri, 25 Apr 2025 07:05:00 -04008349b679-399b-44b2-b8d7-6b7ccffac21dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Present-Real-World-Data-at-Digestive-Disease-Week-2025-on-Adoption-of-New-Diagnosis-Codes-Among-Short-Bowel-Syndrome-Patients-Who-Are-Dependent-on-Parenteral-Support/default.aspxTue, 22 Apr 2025 16:05:00 -040067357ed1-f06e-448b-9d71-19d3a90c5174https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Provides-Clinical-and-Regulatory-Update-on-Apraglutide/default.aspxMon, 14 Apr 2025 07:00:00 -0400f9a946f1-d244-4f8b-a85a-4cb8b4e6e0f6https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Non-Compliance-Notification-Regarding-Late-2024-Form-10-K-Filing/default.aspxThu, 27 Mar 2025 16:05:00 -0400cee7e190-268c-4590-b10c-95051d9a33cchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Achieves-2024-Financial-Guidance/default.aspxThu, 27 Feb 2025 07:00:00 -05000f0a93d1-8991-4a0d-8f65-61b41951b4cahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2024-Investor-Update-Call/default.aspxThu, 20 Feb 2025 16:00:00 -0500ae849b98-88f5-470a-bd5e-b2ee767e74d2https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Initiates-Apraglutide-NDA-Submission-Highlights-Compelling-New-Data-and-Updates-Corporate-Structure-to-Position-for-the-Future/default.aspxWed, 29 Jan 2025 16:05:00 -0500de3c4b43-57f5-42ac-b27d-433c40619df5https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference/default.aspxTue, 26 Nov 2024 16:01:00 -05000ff93d6c-e7f8-4bf9-b4eb-d80b8d3e3a65https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-London-Healthcare-Conference/default.aspxWed, 13 Nov 2024 16:01:00 -0500d685d58f-7405-4ba2-8a45-f1cc40a104b9https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2024-Results/default.aspxThu, 07 Nov 2024 07:00:00 -0500f532e743-1e9a-415f-b2d8-9855e260c0e7https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Once-Weekly-Apraglutide-Showed-Consistent-Treatment-Effect-Across-Baseline-Demographics-and-Disease-Characteristics-in-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-According-to-New-STARS-Phase-III-Data-from-Ironwood-at-ACG-2024/default.aspxMon, 28 Oct 2024 07:00:00 -0400b4ff6faf-1652-4ad9-b88d-1401d5565521https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2024-Investor-Update-Call/default.aspxThu, 24 Oct 2024 16:00:00 -0400fc39cce4-707d-431c-a60c-2f9692c5a20bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-2024-Wells-Fargo-Healthcare-Conference/default.aspxThu, 29 Aug 2024 16:01:00 -0400a2d9e72c-35d6-4349-b530-bcce78d132f7https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2024-Results/default.aspxThu, 08 Aug 2024 07:00:00 -040051968e3a-8471-4002-b932-9f998caae9c3https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2024-Investor-Update-Call/default.aspxThu, 25 Jul 2024 16:00:00 -04001444aa98-02aa-4369-b13d-7633c3c87022https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference/default.aspxThu, 30 May 2024 16:01:00 -0400ceae6b33-1917-45c7-b6f8-5a228ed813c5https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Late-Breaker-Oral-Presentation-at-Digestive-Disease-Week-Reinforces-Potential-of-Once-Weekly-Apraglutide-for-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF/default.aspxTue, 21 May 2024 06:00:00 -040083d2f324-7602-4d6f-b1be-f476159ca6b0https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-First-Quarter-2024-Results/default.aspxThu, 09 May 2024 07:00:00 -040050ace93d-5146-4719-80a2-61843aba1825https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-JMP-Life-Sciences-Conference/default.aspxMon, 06 May 2024 16:01:00 -0400ea274c10-6a9c-40fa-ae51-85dad6e53876https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-New-Data-on-Once-Weekly-Apraglutide-in-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-at-Digestive-Disease-Week-2024/default.aspxWed, 01 May 2024 07:30:00 -0400e3b21747-e303-475b-a9cd-84060d5e5a39https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2024-Investor-Update-Call/default.aspxThu, 25 Apr 2024 16:01:00 -04007d3ee29e-15e1-4c98-af9d-66a78b3aa699https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Results-from-its-Phase-II-Exploratory-STARGAZE-Trial-of-Apraglutide-in-Patients-with-Steroid-Refractory-Gastrointestinal-Acute-Graft-versus-Host-Disease-SR-GI-aGVHD/default.aspxThu, 28 Mar 2024 07:30:00 -0400d5a47fa0-3435-4596-a0d4-0e45bf343b56https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Topline-Results-from-Global-Phase-III-Trial-of-Once-Weekly-Apraglutide-in-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF/default.aspxThu, 29 Feb 2024 06:00:00 -05001abfa1fc-5616-4e02-a0fc-c16072586411https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-Four-Abstracts-at-the-ASPEN-2024-Nutrition-Science--Practice-Conference/default.aspxFri, 23 Feb 2024 07:30:00 -0500eb5e0b24-ad0e-47f2-8f93-b85323148d4bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Results-Achieves-2023-Financial-Guidance/default.aspxThu, 15 Feb 2024 07:00:00 -0500fc7bd0dd-75ec-46f2-a5e5-055c7dff19e7https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2023-Investor-Update-Call/default.aspxThu, 01 Feb 2024 16:01:00 -050014e11de9-0dfa-4493-8fbc-ef1be9b7cc4ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Announces-Publication-in-The-Lancet-Gastroenterology--Hepatology-of-New-Linaclotide-Phase-III-Data-in-Children-and-Adolescents-Aged-6-17-Years-with-Functional-Constipation/default.aspxMon, 08 Jan 2024 19:00:00 -05001d9b27fe-f3b4-46f6-8a41-808b103c8cb5https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Maintains-FY-2023-Financial-Guidance-and-Announces-FY-2024-Financial-Guidance/default.aspxMon, 08 Jan 2024 06:00:00 -050044942320-31c3-468a-bdad-7d8c92470b71https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Present-at-the-42nd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspxWed, 03 Jan 2024 16:01:00 -050035abe9db-4a06-4c5d-9868-e40eb35260e1https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Announces-the-Completion-of-Squeeze-Out-Merger-With-VectivBio/default.aspxTue, 12 Dec 2023 16:01:00 -0500315f1fba-6bb1-4a47-bd94-a1eeb808ec17https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-35th-Annual-Healthcare-Conference/default.aspxTue, 21 Nov 2023 16:01:00 -0500f1bf0b86-97c4-4df0-b978-16ec4277c91dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2023-Results/default.aspxThu, 09 Nov 2023 07:00:00 -050031f90c5f-3fb8-4a6f-a784-4403763615f8https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2023-Investor-Update-Call/default.aspxThu, 26 Oct 2023 16:01:00 -0400d70752d1-9b1e-43c8-97d0-192c4a35036fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Releases-New-IBS-C-and-CIC-Data-at-the-American-College-of-Gastroenterology-2023-Annual-Scientific-Meeting/default.aspxMon, 23 Oct 2023 07:30:00 -0400bf573ce3-ee12-41d6-a5ce-721ca3b95350https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Presents-Positive-Final-Data-from-STARS-Nutrition-a-Phase-II-Study-of-Apraglutide-in-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-and-Colon-in-Continuity-CIC-at-United-European-Gastroenterology-Week/default.aspxMon, 16 Oct 2023 06:00:00 -0400fc5aeaba-66ba-42f0-845b-18735c024adahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-to-Present-New-Data-at-NASPGHAN-Annual-Meeting-Reinforcing-Impact-of-Linaclotide-on-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspxThu, 05 Oct 2023 07:30:00 -0400789f0622-0883-419e-b620-33437788a3c5https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2023-Results-Raises-Full-Year-2023-LINZESS-U.S.-Net-Sales-and-Ironwood-Revenue-Guidance/default.aspxTue, 08 Aug 2023 07:00:00 -04008bd5f878-2b0e-4309-8875-d0d9dc317dechttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2023-Investor-Update-Call/default.aspxTue, 25 Jul 2023 16:01:00 -040089f9510a-e8c7-47ac-8a13-a61323d9c352https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-the-Completion-of-the-Tender-Offer-for-VectivBio-Shares/default.aspxThu, 29 Jun 2023 08:30:00 -04004cdc0bf6-9516-4097-926a-6b0e5a6ab1dbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-and-VectivBio-Announce-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Proposed-Acquisition-of-VectivBio/default.aspxFri, 16 Jun 2023 07:00:00 -0400ddd0955e-7199-44d7-a2cf-0911068a0e56https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Announces-FDA-Approval-of-New-Indication-for-LINZESS-linaclotide-for-the-Treatment-of-Functional-Constipation-in-Pediatric-Patients-Ages-6-17-Years-Old/default.aspxMon, 12 Jun 2023 16:05:00 -0400bd52ef0b-5ecb-4165-a597-38b0410bffebhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Enters-into-Definitive-Agreement-to-Acquire-VectivBio-a-Clinical-Stage-Biotech-Company-Pioneering-Novel-Treatments-for-Severe-Rare-Gastrointestinal-Diseases/default.aspxMon, 22 May 2023 06:57:00 -040023b86889-2f33-4ceb-b3ff-83f38aadd312https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-The-JMP-Securities-Life-Sciences-Conference/default.aspxTue, 09 May 2023 16:01:00 -0400e0406516-4149-4272-9df7-4a95c8de952fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Presents-New-Data-on-Potential-of-Linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old-at-Digestive-Disease-Week-2023/default.aspxMon, 08 May 2023 07:30:00 -0400b65c2281-1efa-487a-a7d9-68b28a9b39e3https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-First-Quarter-2023-Results-Maintains-Full-Year-2023-Financial-Guidance/default.aspxThu, 04 May 2023 07:00:00 -04006531edde-8359-4174-8900-4806faa17223https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-to-Present-New-Data-at-Digestive-Disease-Week-2023-Demonstrating-Potential-of-Linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspxMon, 24 Apr 2023 07:30:00 -0400251cca8b-2641-432d-89c5-bbf820f65240https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2023-Investor-Update-Call/default.aspxThu, 20 Apr 2023 16:01:00 -0400b0452e82-96da-476c-82d0-f9f654c7e32ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences/default.aspxMon, 27 Feb 2023 16:01:00 -05005bfb5a5a-ff01-4517-8dc1-c475b578ae00https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Results/default.aspxThu, 16 Feb 2023 07:00:00 -0500bac69c30-c22f-4a30-99b7-fbbd0a5dd819https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Announces-FDA-Filing-Acceptance-and-Priority-Review-of-Supplemental-New-Drug-Application-forLINZESS-linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-Ages-6-17-Years-Old/default.aspxMon, 13 Feb 2023 07:30:00 -050092c53acb-ead4-4415-81a4-89d8bddca4f1https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2022-Investor-Update-Call/default.aspxThu, 02 Feb 2023 16:01:00 -05005e988b0e-e7a4-416c-9595-c20d960bff2bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Provides-Update-on-FY-2022-Financial-Guidance-and-Announces-FY-2023-Financial-Guidance/default.aspxMon, 09 Jan 2023 06:00:00 -05008127139b-94b9-47d2-856e-0632f0ad0109https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-to-Present-at-the-41st-Annual-J.P.-Morgan-Healthcare-Conference/default.aspxWed, 04 Jan 2023 16:01:00 -05003b9e39fe-aa27-4bd1-9e1d-50b10cf5de79https://news.abbvie.com/news/press-releases/abbvie-submits-supplemental-new-drug-application-to-us-fda-to-support-new-indication-linzess-linaclotide-for-functional-constipation-in-children-and-adolescents-6-to-17-years-age.htmFri, 16 Dec 2022 00:00:00 -0500923674d7-8301-4565-9047-a71c8fcfa5c5https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-34th-Annual-Healthcare-Conference/default.aspxTue, 22 Nov 2022 16:01:00 -050040f8c639-f342-484a-b922-e99ff1b554f9https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2022-Results-Maintains-Full-Year-2022-Financial-Guidance/default.aspxThu, 03 Nov 2022 07:01:00 -04007ce5bc0f-36d5-42ec-be00-58c171446deahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2022-Investor-Update-Call/default.aspxThu, 20 Oct 2022 16:01:00 -040029504568-3241-4d7f-bf02-d3304a72c1c6https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Positive-Topline-Data-from-Phase-III-Trial-of-LINZESS-linaclotide-in-Pediatric-Patients-Aged-6-17-with-Functional-Constipation/default.aspxTue, 06 Sep 2022 07:00:00 -0400178c31a1-2e68-410a-a793-2cfdb070e815https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-at-the-2022-Wells-Fargo-Healthcare-Conference/default.aspxThu, 01 Sep 2022 16:01:00 -0400bc5cc91c-1cf4-45be-9714-08032968231ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2022-Results-Maintains-Full-Year-Guidance-Due-to-Continued-Strength-of-LINZESS-Prescription-Demand/default.aspxThu, 04 Aug 2022 07:00:00 -040038ee6b25-b945-4762-bc27-d6c687dcb6c3https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2022-Investor-Update-Call/default.aspxThu, 21 Jul 2022 16:01:00 -040056c5abb7-ef2f-444d-992a-1bd43354adbbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Presents-New-Data-Demonstrating-Potential-of-IW-3300-for-Visceral-Pain-at-Digestive-Disease-Week-DDW-2022/default.aspxWed, 25 May 2022 07:30:00 -0400275f5dbd-c430-498d-b6de-d2854f1fd983https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-New-IW-3300-and-Linaclotide-Data-at-Digestive-Disease-Week-2022/default.aspxMon, 09 May 2022 08:00:00 -0400e11b131b-0339-4ca1-ac53-d286c26da7f1https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-First-Quarter-2022-Results-Maintains-Full-Year-2022-Financial-Guidance/default.aspxThu, 05 May 2022 07:00:00 -0400b060b752-39f4-493d-ae68-84a7428c486ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2022-Investor-Update-Call/default.aspxThu, 21 Apr 2022 16:01:00 -04008bedad31-f718-40ff-8fe1-519259e7bdffhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences/default.aspxWed, 02 Mar 2022 07:30:00 -050071a8d7f9-693f-4d91-8cd7-202bdab58f62https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2021-Results-LINZESS-linaclotide-Achieves-Blockbuster-Status-as-U.S.-Net-Sales-Exceed-1-Billion-in-2021/default.aspxThu, 17 Feb 2022 07:00:00 -05000108156c-41e2-48df-b10d-17ea09363cb9https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2021-Investor-Update-Call/default.aspxThu, 03 Feb 2022 07:30:00 -0500547b2b29-372d-4cc0-bfa5-7dd1386c07dbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Provides-Update-on-FY-2021-Financial-Guidance-and-Announces-FY-2022-Financial-Guidance/default.aspxMon, 10 Jan 2022 07:20:00 -0500a386a1ce-3318-4b3a-8e11-7b67a52fffbfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-at-the-40th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspxWed, 05 Jan 2022 07:30:00 -0500eae9a006-7e23-44d4-9688-5052c230099dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Appoints-Sravan-K.-Emany-as-Chief-Financial-Officer/default.aspxWed, 01 Dec 2021 07:30:00 -05000e83b370-0e8e-4d34-aa6b-0be947ab1c4dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2021-Results-and-Provides-Corporate-Development-Update/default.aspxThu, 04 Nov 2021 07:15:00 -04001749cdb8-4bae-4acd-b8ab-121b69e7244fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Expands-Pipeline-by-Signing-an-Option-Agreement-to-Acquire-an-Exclusive-License-with-COUR-Pharmaceuticals-to-Develop-and-Commercialize-CNP-104-for-the-Treatment-of-Primary-Biliary-Cholangitis-PBC-in-the-U.S/default.aspxThu, 04 Nov 2021 07:00:00 -04005e390cd2-234c-4758-b1ac-48286e25a583https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-than-90-of-Surveyed-IBS-C-Patients-Who-Had-an-ER-Visit-or-Hospitalization-in-the-Past-Year-Identified-Abdominal-Pain-as-a-Symptom-That-Led-to-the-Visit-According-to-Data-Announced-by-Ironwood-Pharmaceuticals-at-ACG-2021/default.aspxMon, 25 Oct 2021 07:30:00 -0400e80917de-a7cb-4080-96e8-cc85dc74a816https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2021-Investor-Update-Call/default.aspxThu, 21 Oct 2021 07:00:00 -0400608a20fe-263f-4185-b9a2-e9fed92d91e8https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Participate-in-Upcoming-September-Investor-Conferences/default.aspxThu, 02 Sep 2021 07:30:00 -0400f74f9340-a5da-40df-b8a1-494853a00920https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-FDA-Approval-of-Revised-LINZESS-linaclotide-Label/default.aspxThu, 26 Aug 2021 07:00:00 -0400fb0d613c-bf40-4fb6-bda7-a2c97c448cb9https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-Strong-Second-Quarter-2021-Results-Raises-Full-Year-Guidance/default.aspxThu, 05 Aug 2021 07:00:00 -0400c656ebbf-260b-4cf9-aa4d-297eab5f9116https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Appoints-John-Minardo-as-Chief-Legal-Officer/default.aspxTue, 03 Aug 2021 07:30:00 -0400e80f2662-c7bb-446c-8a0d-da4ce1ac093dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2021-Investor-Update-Call/default.aspxThu, 22 Jul 2021 16:01:00 -040060679b9f-ff18-4aef-ac88-185a99963388https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-That-The-American-Journal-of-Gastroenterology-Publishes-Full-Results-from-Positive-LINZESS-linaclotide-Phase-IIIb-Trial-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspxWed, 16 Jun 2021 07:45:00 -04009fa38405-66fe-4100-b67a-1c5ef75b2796https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Leadership-Updates/default.aspxMon, 07 Jun 2021 16:01:00 -0400693d393c-289c-4ad2-8074-2517041be245https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Agreement-with-Teva-Involving-LINZESS-linaclotide-72-mcg-Dosage-Strength/default.aspxWed, 26 May 2021 16:01:00 -0400a05e7374-40e2-4bd1-ae13-7f80182a4112https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-Than-a-Third-of-Surveyed-IBS-C-Patients-Reported-That-Their-Symptoms-Worsened-During-COVID-19-According-to-New-Survey-Findings-Presented-by-Ironwood-Pharmaceuticals-at-Digestive-Disease-Week-DDW/default.aspxMon, 24 May 2021 08:00:00 -040017320ddf-f85b-458e-80f6-f083579516c8https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Present-New-Linaclotide-Data-and-Unveil-Findings-From-GI-Disease-Surveys-at-Digestive-Disease-Week-2021/default.aspxMon, 17 May 2021 08:30:00 -04003bbab2e3-c8d3-41bc-b4af-02782c1afc3ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-New-150-Million-Share-Repurchase-Program/default.aspxThu, 06 May 2021 07:03:00 -040070ce20e9-8356-464e-9493-3a25abdf1a1ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-First-Quarter-2021-Results/default.aspxThu, 06 May 2021 07:00:00 -0400d3ac34e8-0e94-4b21-a854-9e2866d3cdcdhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2021-Investor-Update-Call/default.aspxThu, 22 Apr 2021 16:01:00 -040096c653a4-da35-4f0a-841d-cdf903bd5bbchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences/default.aspxFri, 19 Feb 2021 16:01:00 -050076b95d6a-a8ce-484b-81a0-db330e0f13a5https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2020-Results-Exceeding-or-Meeting-Full-Year-2020-Financial-Guidance-Provides-Full-Year-2021-Financial-Guidance/default.aspxWed, 17 Feb 2021 07:01:00 -050096caade8-d2bc-47bf-bef1-cc33aa707caahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-CEO-Transition/default.aspxMon, 08 Feb 2021 16:01:00 -0500ad80e862-af0d-4b76-b010-d336788a1062https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2020-Investor-Update-Call/default.aspxWed, 03 Feb 2021 16:01:00 -05008ab09667-346d-4e4e-b5fe-45926f57fc5ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Present-at-the-39th-Annual-J.P.-Morgan-Healthcare-Conference/default.aspxTue, 05 Jan 2021 07:30:00 -0500fd82979a-17dc-4fa5-8f07-a3c258ac09cdhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Appoints-Jay-P.-Shepard-to-Board-of-Directors/default.aspxThu, 03 Dec 2020 08:30:00 -050071e7dcb9-0e29-423e-bbf5-5b8908db45eehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Present-at-the-29th-Annual-Credit-Suisse-Healthcare-Conference/default.aspxFri, 06 Nov 2020 16:01:00 -05009d6e53d1-ade8-4c87-9c7d-a1c17639192bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2020-Results-and-Increases-Full-Year-2020-Financial-Guidance/default.aspxThu, 05 Nov 2020 16:03:00 -05007c0f30dd-377f-4f45-bde8-ea4c205d811fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Appoints-Alexander-Denner-Ph.D.-to-Board-of-Directors/default.aspxThu, 05 Nov 2020 16:01:00 -0500eba13220-53bb-4cc6-a456-1e165c388a1fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2020-Investor-Update-Call/default.aspxThu, 22 Oct 2020 16:01:00 -0400a8796655-f222-44e7-b221-5d41b0565581https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-to-Discontinue-IW-3718-Development-Program-Following-Results-from-Planned-Efficacy-Assessment/default.aspxTue, 29 Sep 2020 07:15:00 -04007eb41525-1f5d-4e39-b3af-eec9e9b0e946https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Participate-in-Upcoming-September-Investor-Conferences/default.aspxWed, 02 Sep 2020 16:00:00 -0400ef2fbd0f-1724-48b7-8cc7-dbe61ace08cahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2020-Results-Delivered-GAAP-Net-Income-of-25-Million-and-Adjusted-EBITDA-of-33-Million/default.aspxThu, 06 Aug 2020 07:00:00 -0400fe9d918b-0e37-49c1-8b29-a73d0b4c3ab7https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2020-Investor-Update-Call/default.aspxThu, 23 Jul 2020 16:05:00 -040022b6fff3-71b2-4447-b3b5-ff5154b13acbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Announces-Updates-Designed-to-Strengthen-IW-3718-Phase-III-Program-for-Refractory-Gastroesophageal-Reflux-Disease-GERD/default.aspxTue, 21 Jul 2020 07:00:00 -0400cc42d867-f9d2-4943-9d2d-8875fcbb5811https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-AbbVie-Report-Top-line-Phase-II-Data-for-MD-7246-in-Patients-with-Abdominal-Pain-Associated-with-Irritable-Bowel-Syndrome-with-Diarrhea-IBS-D/default.aspxWed, 27 May 2020 08:00:00 -0400bf117e0e-5db9-4840-9f1c-1840e28ec90ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-First-Quarter-2020-Results-and-Provides-Update-on-Impact-of-COVID-19-Pandemic/default.aspxWed, 06 May 2020 16:05:00 -0400e4593a80-dce9-44b4-9ace-b6b524749fe6https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-Allergan-Receive-Notices-of-Allowance-for-Patent-Applications-Covering-72-mcg-Dose-of-LINZESS-linaclotide/default.aspxTue, 28 Apr 2020 16:05:00 -04007b2a1acd-379c-4f4b-b0bb-967bcab6f402https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2020-Investor-Update-Call/default.aspxThu, 16 Apr 2020 16:05:00 -04008c19aebe-69ab-4409-83e4-1e750c8d0733https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Provides-Update-on-Impact-of-COVID-19/default.aspxThu, 26 Mar 2020 09:00:00 -0400dc4c54c2-ff13-4050-892c-801c2e866633https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/COVID-19-IRWD-Public-Letter/default.aspxSat, 14 Mar 2020 18:00:00 -0400d17a9912-5afe-428f-bf51-bed63f75f7achttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Announces-Publication-of-Positive-IW-3718-Phase-IIb-Data-in-Gastroenterology/default.aspxWed, 26 Feb 2020 16:05:00 -0500df731642-7585-4e32-a862-86fc3bcddc05https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-March-Investor-Conferences/default.aspxTue, 25 Feb 2020 16:05:00 -05004b7fe597-f01c-4674-85a2-f47109e91563https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Present-at-SVB-Leerink-Global-Healthcare-Conference/default.aspxWed, 19 Feb 2020 16:05:00 -05009ca8d65b-d8d9-4e73-a282-4d0f8e576d48https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Reports-Strong-Fourth-Quarter-and-Full-Year-2019-Results-Exceeding-Full-Year-2019-Guidance-Provides-Full-Year-2020-Guidance/default.aspxThu, 13 Feb 2020 07:00:00 -05009b3d74c4-0269-481c-aa65-ec7251baef39https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2019-Investor-Update-Call/default.aspxThu, 30 Jan 2020 16:05:00 -050068ae9a5b-acec-466c-95cc-aa4ac42de815https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-Allergan-Announce-Settlement-with-Teva-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspxWed, 22 Jan 2020 09:20:00 -0500e85506f5-ac30-4621-bbae-b586c4519c6ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-and-Allergan-Announce-Settlement-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspxMon, 06 Jan 2020 08:00:00 -0500abb69b51-092d-40ab-a4b5-b0623c23cb05https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxThu, 02 Jan 2020 16:01:00 -05008feabf3d-8d6d-4e6c-ad58-214512be76dchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-the-28th-Annual-Credit-Suisse-Healthcare-Conference/default.aspxTue, 05 Nov 2019 16:05:00 -050079a07d88-0532-4385-ae3d-c1a2fd82502ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2019-Results-Raises-Full-Year-2019-Guidance/default.aspxThu, 31 Oct 2019 07:00:00 -0400e1d6656d-37aa-4f6b-8a2b-f0d796bc1484https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Highlight-New-Data-at-the-American-College-of-Gastroenterology-2019-Annual-Scientific-Meeting/default.aspxMon, 28 Oct 2019 08:00:00 -0400b47488a4-305a-4727-8ad2-dcd4461c180chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2019-Investor-Update-Call/default.aspxThu, 17 Oct 2019 16:05:00 -04008360b888-780e-4aa6-9942-d01793e828c1https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-AstraZeneca-Amend-LINZESS-linaclotide-Collaboration-in-China/default.aspxWed, 18 Sep 2019 00:00:00 -040096c71328-4efd-46be-a68b-00932ebbf563https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences/default.aspxWed, 28 Aug 2019 16:05:00 -04008bd1f355-9096-4e76-ae71-b926115b0fc8https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Full-Exercise-of-Convertible-Notes-Over-Allotment/default.aspxTue, 13 Aug 2019 16:50:00 -040071a02d4e-e99c-44f4-8949-6cea2753a31fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-Alnylam-Pharmaceuticals-Enter-US-GI-Disease-Education-and-Promotional-Agreement-for-Alnylams-Givosiran-in-Acute-Hepatic-Porphyria-AHP/default.aspxTue, 13 Aug 2019 07:30:00 -040093ca82c5-382b-41e7-a088-4c039302b403https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Pricing-of-Upsized-350-Million-Convertible-Senior-Notes-Offering/default.aspxThu, 08 Aug 2019 07:30:00 -04007bed2af6-b59f-45ff-b12e-001d81201d60https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announced-Proposed-Offering-of-330-Million-of-Convertible-Senior-Notes/default.aspxTue, 06 Aug 2019 16:05:00 -040080aaec51-6f48-487d-a5aa-a21c9ad429f4https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2019-Results/default.aspxTue, 30 Jul 2019 16:01:00 -04005c498799-9f06-4fd6-bf43-e49d7c8568cahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2019-Investor-Update-Call/default.aspxThu, 18 Jul 2019 16:05:00 -040013deb97b-34f1-4305-893a-dda8eb2a0b2fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-and-Allergan-Report-Positive-Topline-Data-from-Phase-IIIb-Trial-of-LINZESS-linaclotide-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspxTue, 18 Jun 2019 16:05:00 -0400054ae2bf-edb4-498e-ac7b-388126c6fdb3https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Establish-New-Headquarters-in-Downtown-Boston/default.aspxThu, 13 Jun 2019 16:30:00 -040060d494b4-68c1-4749-86b8-bd32652f5be8https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-Allergan-Initiate-Patient-Dosing-in-Phase-II-Clinical-Trial-of-MD-7246-in-Patients-with-Abdominal-Pain-Associated-with-IBS-D/default.aspxMon, 03 Jun 2019 08:30:00 -04003889e01f-f5d5-4b60-9905-7933a1116396https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Highlight-IW-3718-and-Linaclotide-Data-at-Digestive-Disease-Week-2019/default.aspxThu, 09 May 2019 08:00:00 -0400cb2bca46-4a20-4407-b761-07ead0f1e8cahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-the-2019-Bank-of-America-Merrill-Lynch-Healthcare-Conference/default.aspxTue, 07 May 2019 16:05:00 -0400b916b37d-74f1-4cc1-a846-4c530ae0f523https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Reports-First-Quarter-2019-Results-Announces-Positive-2019-Adjusted-EBITDA-from-Continuing-Operations-Guidance/default.aspxThu, 02 May 2019 07:00:00 -040073be8c6b-aa9c-440c-842a-4878bfe71522https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2019-Investor-Update-Call/default.aspxThu, 18 Apr 2019 16:05:00 -0400bbaf6f95-2eac-4978-be4c-1a590e6be69dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Adjustment-of-Conversion-Rate-for-its-225-Convertible-Senior-Notes-due-2020/default.aspxTue, 16 Apr 2019 16:02:00 -040024c619b9-cbb5-47a5-98e0-f34884978f42https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Completes-Separation-of-Cyclerion-Therapeutics-and-Becomes-a-Gastrointestinal-GI-focused-Healthcare-Company/default.aspxMon, 01 Apr 2019 16:02:00 -04002fdfe370-5afd-4469-a638-0de17deef336https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Announces-Effectiveness-of-Cyclerion-Form-10-Registration-Statement/default.aspxThu, 14 Mar 2019 16:54:00 -0400d8f2aab3-3cda-41ed-a6e8-308879834a39https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-Barclays-Global-Healthcare-Conference/default.aspxThu, 07 Mar 2019 16:05:00 -05005e935717-85a8-49bd-8766-3147036a19bdhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-Cowen-Health-Care-Conference/default.aspxMon, 04 Mar 2019 16:05:00 -0500e72118c6-fcdc-421a-9698-1416478dcb2bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Cyclerion-the-Planned-RD-Spin-off-of-Ironwood-Pharmaceuticals-Secures-Commitments-of-175-Million-in-Private-Offering/default.aspxTue, 26 Feb 2019 09:00:00 -0500bf8b35d9-f482-49b0-94eb-ea962ca04577https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-SVB-Leerink-Global-Healthcare-Conference/default.aspxThu, 21 Feb 2019 16:05:00 -0500c7fd52ad-8918-4593-84d4-d6b7650d21e9https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-and-Full-Year-2018-Investor-Update/default.aspxWed, 13 Feb 2019 07:00:00 -0500b8c9fa3a-6aea-43e3-95c6-287e0df5c748https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2018-Investor-Update-Call/default.aspxMon, 28 Jan 2019 17:00:00 -0500d0dc7143-d5ed-4ba9-8bdf-ece4b5fd352dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Announces-Filing-of-Form-10-Registration-Statement-in-Connection-with-Planned-Business-Separation/default.aspxMon, 28 Jan 2019 08:30:00 -0500cd86d21b-2d88-442f-af32-c298360dc60bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Approval-of-LINZESS-linaclotide-in-China-for-the-Treatment-of-Adults-with-IBS-C/default.aspxTue, 15 Jan 2019 08:00:00 -05008d4bafc3-7932-4c61-872e-9a29023d1548https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Appoints-Michael-Shetzline-MD-PhD-as-Chief-Medical-Officer/default.aspxSun, 06 Jan 2019 00:00:00 -0500b996fff8-08fc-4afd-883b-8f045bf82b04https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Chief-Executive-Officers-to-Lead-Ironwood-and-Cyclerion-Effective-Upon-Upcoming-Separation/default.aspxFri, 04 Jan 2019 00:00:00 -05006e552b2c-ab0b-43b8-ab93-387234d52a2ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference/default.aspxWed, 02 Jan 2019 00:00:00 -05008e814326-bdc7-4e7a-a917-fa97a9525a3chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-and-Allergan-Announce-Settlement-with-Mylan-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspxWed, 02 Jan 2019 00:00:00 -050049aab5a1-372b-4c5c-83e4-3f341eb4114chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-27th-Annual-Credit-Suisse-Healthcare-Conference/default.aspxThu, 08 Nov 2018 00:00:00 -050050a255e6-5ccc-4074-a43a-d0a556e52172https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2018-Investor-Update/default.aspxTue, 06 Nov 2018 00:00:00 -05000432d141-2f04-4f6f-8107-fac0f425f06ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2018-Investor-Update-Call/default.aspxThu, 25 Oct 2018 00:00:00 -04000ad2b843-51c7-4c09-8766-f72d85b3f41chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Presenting-IW-3718-and-Linaclotide-Data-at-the-American-College-of-Gastroenterology-2018-Annual-Scientific-Meeting/default.aspxMon, 08 Oct 2018 00:00:00 -04001e6880ee-28cc-4ad8-8a3b-3ed30aecedefhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-FDA-Fast-Track-Designation-for-Praliciguat-for-the-Treatment-of-Heart-Failure-with-Preserved-Ejection-Fraction-HFpEF/default.aspxThu, 13 Sep 2018 00:00:00 -040005e3a81f-a19a-478e-a98b-529756c354c0https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences/default.aspxTue, 28 Aug 2018 00:00:00 -040042da4356-01ec-4c78-96d7-5ddfc2782605https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Approval-of-LinzessTablets-025-mg-in-Japan-for-Additional-Indication-of-Chronic-Constipation/default.aspxTue, 21 Aug 2018 00:00:00 -040025b080ba-6a2e-416b-9696-7cf46b1a2639https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2018-Investor-Update/default.aspxMon, 06 Aug 2018 00:00:00 -0400d8fd4216-41b7-4dee-98e9-1224dd46fcd1https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2018-Investor-Update-Call/default.aspxMon, 23 Jul 2018 00:00:00 -0400880ad074-c30b-4b39-8469-e500dfaa9180https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Initiates-Phase-IIIb-Study-of-Linaclotide-in-Adult-Patients-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspxMon, 16 Jul 2018 00:00:00 -0400dc6bbe07-ba39-408c-b5ba-0ed23a7f8947https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Presents-Praliciguat-Phase-IIa-Study-Data-Showing-Positive-Impact-on-Metabolic-and-Cardiovascular-Clinical-Endpoints-at-the-American-Diabetes-Associations-78th-Scientific-Sessions/default.aspxSat, 23 Jun 2018 00:00:00 -0400c26deab6-e478-4dec-a9a7-ab4f5b4c815dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Initiates-Pivotal-Phase-III-Program-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease/default.aspxThu, 21 Jun 2018 00:00:00 -040015a3ae8b-e401-4e39-8e9e-da0e17e22637https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-and-Preclinical-Data-for-Praliciguat-at-the-American-Diabetes-Associations-78th-Scientific-Sessions/default.aspxWed, 20 Jun 2018 00:00:00 -0400b100b255-cbac-4de1-8c7d-2ca7ac14159ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-FDA-Orphan-Drug-Designation-for-Olinciguat-for-the-Treatment-of-Sickle-Cell-Disease/default.aspxThu, 07 Jun 2018 00:00:00 -04004fc17f1c-48dc-42f3-98dc-52409c72712ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-39th-Annual-Global-Healthcare-Conference/default.aspxWed, 06 Jun 2018 00:00:00 -0400b1fdf084-e1de-4a1f-b6d8-9e0a23181cb5https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Presents-IW-3718-Data-Showing-Improvements-in-Heartburn-and-Regurgitation-Symptoms-in-Patients-with-Persistent-GERD-at-Digestive-Disease-Week-2018/default.aspxTue, 05 Jun 2018 00:00:00 -04001aa5af05-f209-4000-86e1-0341322876abhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-Results-of-2018-Annual-Meeting-of-Shareholders/default.aspxThu, 31 May 2018 00:00:00 -04006da40ef7-f4e0-4610-8588-200c1dace1b6https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Highlight-Clinical-Data-for-IW-3718-in-Persistent-Gastroesophageal-Reflux-Disease-GERD-at-Digestive-Disease-Week-2018/default.aspxWed, 23 May 2018 00:00:00 -04009c0c99c9-8332-4fb1-ad3f-fc110b1a269dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Sends-Letter-to-Shareholders-Highlighting-Director-Nominees/default.aspxMon, 14 May 2018 00:00:00 -040059730751-d076-4ec6-85a8-18fb520ca40fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Investor-Presentation-Highlighting-Actions-Taken-Designed-to-Unlock-Shareholder-Value/default.aspxWed, 09 May 2018 00:00:00 -04003a4e432a-1860-46b5-aa54-a1caf22fcf02https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-and-Allergan-Announce-Settlement-with-Aurobindo-Pharma-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspxThu, 03 May 2018 00:00:00 -0400df1fd350-f743-4ba8-b4e8-095c819b8498https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Files-Definitive-Proxy-Materials-and-Mails-Letter-to-Shareholders/default.aspxWed, 02 May 2018 00:00:00 -04001bb84f5d-9657-40d1-8f2b-25340116a3e0https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-Intent-to-Separate-Soluble-Guanylate-Cyclase-sGC-Business-from-Commercial-and-Gastrointestinal-Business/default.aspxTue, 01 May 2018 00:00:00 -0400e396847a-389d-4c3b-9368-a1cd4605840dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Provides-First-Quarter-2018-Investor-Update/default.aspxTue, 01 May 2018 00:00:00 -04002a97dc0e-ce82-45fe-9e80-d95fcbd1a2bfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Allergan-and-Ironwood-Launch-Interactive-Digital-Destination-During-Irritable-Bowel-Syndrome-IBS-Awareness-Month-Designed-to-Encourage-Sufferers-to-Get-Educated-and-Take-Action/default.aspxTue, 01 May 2018 00:00:00 -04006dda75df-ec22-458a-bc70-d89dc93ab24ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2018-Investor-Update-Call/default.aspxTue, 17 Apr 2018 00:00:00 -04006a35b7ed-2c4a-453a-be87-6bb8e0f59c64https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Announces-Director-Nomination-from-Sarissa-Capital/default.aspxMon, 09 Apr 2018 00:00:00 -0400fdd0e42b-2746-4d16-898d-170088b10a6bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-March-Investor-Conferences/default.aspxMon, 05 Mar 2018 00:00:00 -05002d5bf822-0ab6-496e-8cd4-961d6af6a349https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-and-Full-Year-2017-Investor-Update/default.aspxThu, 15 Feb 2018 00:00:00 -05001a484294-7cde-4b97-b857-81c72f381d33https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2017-Investor-Update-Call/default.aspxThu, 01 Feb 2018 00:00:00 -05000e369df2-ed0c-4b8c-a459-38929d7303eehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-and-Allergan-Announce-Settlement-with-Sun-Pharma-Resolving-LINZESS-linaclotide-Patent-Litigation/default.aspxTue, 16 Jan 2018 00:00:00 -0500e16e29f1-b9c5-4787-85b4-b2dbe2aecb31https://investor.ironwoodpharma.com/press-releases/press-release-details/2018/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20180102000000/default.aspxTue, 02 Jan 2018 00:00:00 -0500e60498aa-4d2b-4145-8d25-6a095c7b8f52https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Initiates-Phase-II-Clinical-Trial-of-sGC-Stimulator-IW-1701-in-Patients-with-Sickle-Cell-Disease/default.aspxThu, 21 Dec 2017 00:00:00 -0500671035bf-57b8-43f7-b842-b8efa4d1624ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Reports-Top-line-Phase-IIa-Data-for-IW-1973-Demonstrating-Positive-Cardiovascular-Metabolic-and-Endothelial-Effects/default.aspxMon, 04 Dec 2017 00:00:00 -0500f9fbbcf6-0eb7-46f1-a2f3-cc516697ff79https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Strengthens-Executive-Leadership-Team/default.aspxTue, 28 Nov 2017 00:00:00 -0500ca207a93-638b-4c5c-b4b7-81b0554c4854https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2017-Investor-Update/default.aspxThu, 02 Nov 2017 00:00:00 -0400ec15db25-8122-4d42-a832-c223ef94a98bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-26th-Annual-Healthcare-Conference/default.aspxWed, 01 Nov 2017 00:00:00 -0400fc10b591-195c-4b0b-8dfd-086cf843c6e0https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Highlights-Breadth-of-Gout-Research-to-be-Presented-at-the-2017-ACRARHP-Annual-Meeting/default.aspxMon, 30 Oct 2017 00:00:00 -04001540322f-35c3-41dc-b40f-4263dd36d803https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2017-Investor-Update-Call/default.aspxThu, 19 Oct 2017 00:00:00 -04005360621b-780b-479b-bcac-88eca16de316https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Presenting-Linaclotide-Data-at-the-World-Congress-of-Gastroenterology-at-ACG-2017/default.aspxMon, 16 Oct 2017 00:00:00 -0400ead037fa-3f89-4c04-bf37-139290f112dahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Announces-Leadership-Change/default.aspxWed, 06 Sep 2017 00:00:00 -0400ff206364-3ad0-4549-97ee-48afaa634489https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-September-Investor-Conferences-20170831000000/default.aspxThu, 31 Aug 2017 00:00:00 -0400699e9aae-109c-4ab3-812e-ac193468a564https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Announces-FDA-Approval-of-DUZALLO-lesinurad-and-allopurinol-for-the-Treatment-of-Hyperuricemia-in-Patients-with-Uncontrolled-Gout/default.aspxMon, 21 Aug 2017 00:00:00 -040040b2c3fd-4ea9-4d24-b982-1fa5c57f295ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2017-Investor-Update/default.aspxThu, 03 Aug 2017 00:00:00 -04006a3a3c3a-76dc-41a7-85a4-3f934afa38b0https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Reports-Positive-Top-line-Results-from-IW-3718-Phase-IIb-Trial-in-Uncontrolled-Gastroesophageal-Reflux-Disease/default.aspxThu, 20 Jul 2017 00:00:00 -0400ff8ac801-d2a4-4a5b-8011-c6029b1a7c87https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2017-Investor-Update-Call/default.aspxThu, 20 Jul 2017 00:00:00 -0400635fe91a-408b-494c-b289-d3245a674d70https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-38th-Annual-Global-Healthcare-Conference/default.aspxThu, 08 Jun 2017 00:00:00 -0400315197c4-6101-444b-b303-b3e0f7662fb5https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference/default.aspxThu, 01 Jun 2017 00:00:00 -0400d86b8c3b-010e-40e3-876e-637ee2b2884chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-the-Bank-of-America-Merrill-Lynch-Healthcare-Conference/default.aspxWed, 10 May 2017 00:00:00 -040039bed13c-b728-4b9d-bb4d-b2a0ad1895b3https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Presents-Data-Further-Elucidating-Linaclotides-Effect-on-Pain-at-Digestive-Disease-Week-2017/default.aspxTue, 09 May 2017 00:00:00 -04008c7ef8ea-8302-4b83-b4ef-41d2335e0526https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Provides-First-Quarter-2017-Investor-Update/default.aspxMon, 08 May 2017 00:00:00 -040086470658-0f79-4300-b5bd-1ccc8764093bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-New-Data-for-Linaclotide-Linaclotide-Delayed-Release-and-IW-1701-at-Digestive-Disease-Week-2017/default.aspxMon, 01 May 2017 00:00:00 -0400c6ea252c-2bb0-43fc-8e19-19ba582178b4https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2017-Investor-Update-Call/default.aspxMon, 24 Apr 2017 00:00:00 -040039a02330-0346-46df-92c2-0f56d42dfb3ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Allergan-and-Ironwood-Launch-Campaign-Designed-to-Empower-the-Nearly-64-Million-Americans-Estimated-to-Suffer-from-IBS-and-CIC-to-Talk-About-Bowel-Health1-5/default.aspxThu, 13 Apr 2017 00:00:00 -04006bd1e3ca-eaaf-4574-b040-3c672a7d19e1https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Appoints-Dr-Christopher-Wright-as-Senior-Vice-President-of-Global-Development-and-Chief-Development-Officer/default.aspxThu, 06 Apr 2017 00:00:00 -0400be9b2eeb-b0e6-4b70-8da5-b671ca27a953https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-Barclays-Global-Healthcare-Conference/default.aspxFri, 10 Mar 2017 00:00:00 -0500ed17a99f-81b1-4ae8-ac17-3d05086d5aa8https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Showcases-Progress-Delivering-Innovative-Medicines-to-Patients-and-Building-a-Top-Performing-Commercial-Biotech-at-RD-Day-2017/default.aspxThu, 09 Mar 2017 00:00:00 -05003249b566-b337-4d8d-be55-1c774abd2283https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-37th-Annual-Health-Care-Conference/default.aspxTue, 28 Feb 2017 00:00:00 -0500eb032622-13dd-414b-abf8-ef8ecdf0b6a6https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Host-RD-Day-on-March-9-2017/default.aspxThu, 23 Feb 2017 00:00:00 -050023350edc-5ada-4960-a9f2-9b1b3e7201fchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-and-Full-Year-2016-Investor-Update/default.aspxTue, 21 Feb 2017 00:00:00 -050038e29785-05b2-492f-a809-9122b7cb1d56https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2016-Investor-Update-Call/default.aspxTue, 07 Feb 2017 00:00:00 -05000a9d2734-4d34-4ae4-9d48-81c571a79c6dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Astellas-and-Ironwood-Report-Positive-Top-Line-Results-from-Phase-III-Linaclotide-Trial-for-Patients-with-Chronic-Constipation-Conducted-in-Japan/default.aspxSun, 29 Jan 2017 00:00:00 -05009d4777cd-a2a6-4c5a-bf62-4b4793ad7260https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/US-Food-and-Drug-Administration-Approves-72-mcg-Dose-of-LINZESS-linaclotide-for-Adults-with-Chronic-Idiopathic-Constipation/default.aspxThu, 26 Jan 2017 00:00:00 -050021da8a71-9103-4c2b-ae84-28f564bd07b0https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Demonstrates-Strong-Execution-on-Strategy-to-Build-Top-Performing-Commercial-Biotech/default.aspxSun, 08 Jan 2017 00:00:00 -0500c34e167e-6d8c-4eda-8383-43d5a5be7edchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-Appoints-Amy-Schulman-to-Board-of-Directors/default.aspxWed, 04 Jan 2017 00:00:00 -05000f81eed3-1cea-4a29-bb6d-a9fe2bd36e47https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Announces-New-Drug-Application-for-DUZALLO-Fixed-Dose-Combination-of-Lesinurad-and-Allopurinol-Has-Been-Accepted-for-FDA-Review/default.aspxWed, 04 Jan 2017 00:00:00 -0500ed5c0f1a-73a2-4c24-8777-bfb0d6900929https://investor.ironwoodpharma.com/press-releases/press-release-details/2017/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20170103000000/default.aspxTue, 03 Jan 2017 00:00:00 -0500d83bda1f-7b4f-446f-bbca-d53c80cb7037https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Advancement-of-Linaclotide-Colonic-Release-1-CR1-in-IBS-C/default.aspxThu, 22 Dec 2016 00:00:00 -05003670a18d-09d4-4233-b919-d6231555fb3ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Report-Topline-Phase-IIb-Data-Supporting-Further-Investigation-of-Linaclotide-Colonic-Release-2-CR2-for-Abdominal-Pain-in-Non-Constipation-Subtypes-of-IBS/default.aspxThu, 22 Dec 2016 00:00:00 -050036f7c3c2-de42-4392-a6b9-2c01dc6a1eb7https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Announces-Approval-of-LINZESS-linaclotide-in-Japan-for-the-Treatment-of-Adults-with-IBS-C/default.aspxMon, 19 Dec 2016 00:00:00 -05006b2294e3-51f7-496f-9a8a-f75fb9ece930https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Highlights-ZURAMPIC-lesinurad-Phase-III-Extension-Study-Data-at-the-American-College-of-Rheumatology-2016-Annual-Meeting/default.aspxSun, 13 Nov 2016 00:00:00 -050095ee33bf-b12b-4475-96c4-957a379d97c4https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Stifel-2016-Healthcare-Conference/default.aspxThu, 10 Nov 2016 00:00:00 -0500936f4510-98c2-427f-bfcf-81c8dddabf31https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2016-Investor-Update/default.aspxThu, 03 Nov 2016 00:00:00 -04006970e86d-5376-4008-ae85-78adea05308dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-25th-Annual-Healthcare-Conference/default.aspxTue, 01 Nov 2016 00:00:00 -04006fc41ba3-542b-488f-a0ad-1e08afe4a1a5https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Highlights-Breadth-of-Gout-Research-with-Presentations-at-the-American-College-of-Rheumatology-2016-Annual-Meeting/default.aspxTue, 25 Oct 2016 00:00:00 -04007e556fce-8a7e-46d0-bc62-55894a25ee92https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2016-Investor-Update-Call/default.aspxThu, 20 Oct 2016 00:00:00 -0400ba0674f9-ad62-4a68-8894-18d871fd2a70https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Announces-US-Availability-of-ZURAMPIC-lesinurad-200-mg-Tablets-for-Patients-with-Uncontrolled-Gout/default.aspxMon, 03 Oct 2016 00:00:00 -04008927114b-5a4b-45ae-9fd8-50e39fac6b85https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Nine-in-Ten-Physicians-Agree-Target-Goal-for-Gout-Is-Imperative-Yet-Half-of-Patients-Fail-to-Reach-It-New-Survey-Shows/default.aspxMon, 03 Oct 2016 00:00:00 -0400388bb267-0430-408e-8dc7-a7c385a0cda6https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Closes-150-Million-Debt-Refinancing/default.aspxMon, 26 Sep 2016 00:00:00 -04009b6e3524-fddb-42ce-82b0-e9846f06e474https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference/default.aspxWed, 07 Sep 2016 00:00:00 -04006f316962-1210-4439-9e6b-0b4fffcc7906https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Wells-Fargo-2016-Healthcare-Conference/default.aspxThu, 01 Sep 2016 00:00:00 -0400becfa805-08cb-4de3-9a45-94d8574328adhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2016-Investor-Update/default.aspxThu, 04 Aug 2016 00:00:00 -040009db5346-a7b7-49b1-a5c0-9eca71664c4ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2016-Investor-Update-Call/default.aspxThu, 21 Jul 2016 00:00:00 -0400fbc4313e-5af4-4576-a9dd-7d0bcca0dc63https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-and-Allergan-Announce-Supplemental-New-Drug-Application-for-72-mcg-Linaclotide-in-Chronic-Idiopathic-Constipation-Has-Been-Accepted-for-FDA-Review/default.aspxThu, 09 Jun 2016 00:00:00 -040004b19cd6-fff9-4c5e-ac59-e2f777264dc4https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Jefferies-2016-Healthcare-Conference/default.aspxMon, 06 Jun 2016 00:00:00 -040046aa06c3-a2c1-49f7-92fe-707356a07160https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Closes-US-Transaction-with-AstraZeneca-for-Lesinurad/default.aspxFri, 03 Jun 2016 00:00:00 -04004f8fa1d9-549a-4aa0-8ace-0abac7d97435https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Goldman-Sachs-37th-Annual-Global-Healthcare-Conference/default.aspxWed, 01 Jun 2016 00:00:00 -0400472bd87b-6fea-4dc3-9d02-face83aea2f9https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-2016-UBS-Global-Healthcare-Conference/default.aspxWed, 18 May 2016 00:00:00 -04000e34273b-8aa4-49ee-89db-430ebaf9ad07https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-Linaclotide-Data-at-Digestive-Disease-Week-2016/default.aspxTue, 17 May 2016 00:00:00 -0400e34dfe83-b917-43a7-bb4a-f5c29ddae9ebhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Provides-First-Quarter-2016-Investor-Update/default.aspxMon, 09 May 2016 00:00:00 -0400af603f27-fa89-4526-86f2-eb4b3ba9068ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Bank-of-America-Merrill-Lynch-2016-Health-Care-Conference/default.aspxTue, 03 May 2016 00:00:00 -0400c5521427-c940-4f97-8744-fe586e21f715https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Enters-into-US-Licensing-Agreement-with-AstraZeneca-for-Lesinurad/default.aspxTue, 26 Apr 2016 00:00:00 -04003624b4e2-2ace-450b-8535-226cd7603841https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2016-Investor-Update-Call/default.aspxMon, 25 Apr 2016 00:00:00 -04007589fba5-f0c8-4328-8330-925d7e8773cehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Appoints-Andrew-Dreyfus-to-Board-of-Directors/default.aspxThu, 07 Apr 2016 00:00:00 -04007b388bfc-3d82-4f4a-8620-a802008a95cehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Reports-Top-Line-Data-from-Exploratory-Phase-IIa-Study-of-IW-9179-in-Diabetic-Gastroparesis/default.aspxTue, 05 Apr 2016 00:00:00 -040016e1bbca-0d50-4b59-a6b9-1cfef71f0eb4https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-Clinical-and-Preclinical-Data-on-sGC-Stimulators-at-Upcoming-Scientific-Conferences/default.aspxWed, 30 Mar 2016 00:00:00 -0400995cf305-8e54-40d0-b9e1-cbf8735f3658https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Initiates-Phase-IIb-Clinical-Trial-of-IW-3718-in-Refractory-Gastroesophageal-Reflux-Disease/default.aspxWed, 23 Mar 2016 00:00:00 -040057113175-8407-438f-ba76-0f37b46650ffhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Barclays-Global-Healthcare-Conference-20160309000000/default.aspxWed, 09 Mar 2016 00:00:00 -0500e19cb688-225e-43fa-8b35-a9cc4569504bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-36th-Annual-Health-Care-Conference/default.aspxTue, 01 Mar 2016 00:00:00 -0500c744ab10-c0e2-460f-a999-17a2725a2eb8https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Video-Alert-Updated-2016-Direct-to-Consumer-Awareness-Campaign-Available-for-LINZESS-linaclotide/default.aspxMon, 29 Feb 2016 00:00:00 -05008eca507a-7dac-4135-9412-f23c1eeebc7fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Announces-Filing-by-Astellas-of-New-Drug-Application-in-Japan-with-Linaclotide-for-the-Treatment-of-Adults-with-IBS-C/default.aspxWed, 24 Feb 2016 00:00:00 -0500b11c2a28-e435-44d7-ba4f-743da56de763https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Progresses-Vascular-and-Fibrotic-Disease-Platform-with-Positive-Top-Line-Phase-Ia-Data-on-Soluble-Guanylate-Cyclase-Stimulator-IW-1701/default.aspxThu, 18 Feb 2016 00:00:00 -050058c8eefa-7283-43e3-8fbb-e02b0fe1d5a8https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-and-Full-Year-2015-Investor-Update/default.aspxThu, 18 Feb 2016 00:00:00 -0500e971cd46-88e3-4f0c-b47b-516a941669e5https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-2016-RBC-Capital-Markets-Global-Healthcare-Conference/default.aspxWed, 17 Feb 2016 00:00:00 -0500ec3346aa-df71-4da2-8d98-61e1eb1a6a80https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2015-Investor-Update-Call/default.aspxThu, 04 Feb 2016 00:00:00 -0500adc2f579-c43f-4b56-b003-3809643c5bbfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-Details-Strategy-to-Build-Top-Performing-Commercial-Biotechnology-Company/default.aspxMon, 11 Jan 2016 00:00:00 -0500f364a668-e861-407f-ab50-6a5e41f26503https://investor.ironwoodpharma.com/press-releases/press-release-details/2016/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20160104000000/default.aspxMon, 04 Jan 2016 00:00:00 -05004cd0ea05-5718-4354-ab6c-2a8571a0be4ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Astellas-and-Ironwood-Report-Positive-Top-Line-Data-from-Phase-III-IBS-C-Trial-Conducted-in-Japan/default.aspxMon, 30 Nov 2015 00:00:00 -0500acf7ac38-6608-4c2f-8ad0-9307c4859e15https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Reports-Positive-Top-Line-Data-from-Phase-II-Trial-of-Linaclotide-in-Adult-Patients-With-Opioid-Induced-Constipation/default.aspxMon, 30 Nov 2015 00:00:00 -05007650f7ed-5825-4e39-8a77-5bf0220d19e7https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-24th-Annual-Healthcare-Conference/default.aspxWed, 04 Nov 2015 00:00:00 -050097d903d8-4dbd-48d8-9abd-aec12ee66a45https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2015-Investor-Update/default.aspxTue, 03 Nov 2015 00:00:00 -0500b7ccdb8b-b656-4613-a814-c4acdd41b354https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Initiates-Clinical-Studies-of-Soluble-Guanylate-Cyclase-Stimulators-IW-1973-and-IW-1701/default.aspxTue, 03 Nov 2015 00:00:00 -0500fc7aa75e-c6ba-4c94-9ba2-ca59005b5876https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-and-Allergan-Initiate-Phase-IIb-Clinical-Trial-of-Linaclotide-Colonic-Release-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation/default.aspxMon, 02 Nov 2015 00:00:00 -050043b4ef51-bfd6-4507-aaea-46385e11063ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Allergan-Acquires-Rights-To-Ironwoods-CONSTELLA-Linaclotide-From-Almirall-In-More-Than-40-Countries/default.aspxTue, 27 Oct 2015 00:00:00 -04005898c465-3107-4164-aa48-377a17bda456https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Highlights-Refractory-GERD-and-Constipation-Research-at-the-American-College-of-Gastroenterology-2015-Annual-Scientific-Meeting/default.aspxMon, 19 Oct 2015 00:00:00 -04009425e8ec-f2dd-4bbc-83c8-48e0092fa9ebhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2015-Investor-Update-Call/default.aspxWed, 14 Oct 2015 00:00:00 -04001ddc9677-e8d1-4841-a7c0-98b2921eca00https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Reports-Positive-Top-Line-Results-from-Phase-III-Trial-of-72-mcg-Linaclotide-in-Adults-with-Chronic-Idiopathic-Constipation/default.aspxTue, 13 Oct 2015 00:00:00 -04008e272dac-2754-4a91-b30f-c008c600713ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference-20150910000000/default.aspxThu, 10 Sep 2015 00:00:00 -0400b93ea285-b702-4294-96ab-0f93e9a70fafhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2015-Investor-Update/default.aspxWed, 05 Aug 2015 00:00:00 -0400dfde901a-97db-4f69-a76e-ea999f500e31https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-and-Allergan-Enter-Agreement-to-Co-Promote-VIBERZI-for-Irritable-Bowel-Syndrome-with-Diarrhea-IBS-D-in-the-US/default.aspxWed, 05 Aug 2015 00:00:00 -04006d546f17-cecf-49a6-babb-0d7ed4d57829https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Progresses-sGC-Stimulator-Platform-with-Positive-Top-Line-Phase-I-Data-on-IW-1973/default.aspxWed, 22 Jul 2015 00:00:00 -04008aff08dd-8bac-4e38-8bef-8b50e37a1152https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2015-Investor-Update-Call/default.aspxWed, 15 Jul 2015 00:00:00 -0400546067a4-edcf-45ec-b34d-7fba3e9473f1https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/AstraZeneca-and-Ironwood-Report-Positive-Top-Line-Data-from-Phase-III-IBS-C-Trial-Designed-to-Support-Linaclotide-Approval-in-China/default.aspxWed, 08 Jul 2015 00:00:00 -0400b85f16e7-772b-4a68-a872-c1d980618bb7https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Prices-300-Million-of-Convertible-Senior-Notes/default.aspxWed, 10 Jun 2015 00:00:00 -0400a0a7d8b5-90cb-4e7b-b212-33cd374ffbedhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Announces-Proposed-Offering-of-300-Million-of-Convertible-Senior-Notes/default.aspxMon, 08 Jun 2015 00:00:00 -04000a1ba9c7-8562-427f-ad64-ce1a1e28afb5https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Goldman-Sachs-36th-Annual-Global-Healthcare-Conference/default.aspxThu, 04 Jun 2015 00:00:00 -0400ed36b62e-1282-43d7-b61f-1ddf7d5c0b41https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Presents-Gastrointestinal-Disease-Research-at-Digestive-Disease-Week-2015/default.aspxWed, 13 May 2015 00:00:00 -0400097552ca-8f24-4df9-a9b9-8910006c6024https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Bank-of-America-Merrill-Lynch-2015-Health-Care-Conference/default.aspxThu, 07 May 2015 00:00:00 -0400acf8c27d-c5c7-4263-a2b8-b6845e0348ddhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Provides-First-Quarter-2015-Investor-Update/default.aspxTue, 05 May 2015 00:00:00 -040048fa26ba-f8ec-4a14-ac90-e4c338ac79cahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Appoints-Lawrence-Olanoff-MD-PhD-to-Board-of-Directors/default.aspxThu, 16 Apr 2015 00:00:00 -04009f3cf91e-0852-46ee-b2fe-62f6a7e2d30bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2015-Investor-Update-Call/default.aspxWed, 15 Apr 2015 00:00:00 -040045cdb5dc-beba-4ade-9efb-49b1cecd0e1ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Exact-Sciences-and-Ironwood-Pharmaceuticals-Enter-Co-Promotion-Agreement-for-Cologuard/default.aspxMon, 09 Mar 2015 00:00:00 -0400c288bc15-5d9f-4896-bf02-95782ea8dbf2https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Initiates-Phase-I-Clinical-Study-of-sGC-Stimulator-IW-1973/default.aspxThu, 05 Mar 2015 00:00:00 -05002c355cfb-ea2c-4b8c-97f9-c2ef89cbdd24https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Barclays-Global-Healthcare-Conference-20150304000000/default.aspxWed, 04 Mar 2015 00:00:00 -0500b4845cba-4a69-480a-b09d-86f8d5bbdccchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-35th-Annual-Health-Care-Conference/default.aspxMon, 23 Feb 2015 00:00:00 -0500cba76fb7-901a-4e65-b729-4939100b3b3bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-2014-Investor-Update/default.aspxThu, 12 Feb 2015 00:00:00 -05005450c9e1-9933-4a62-8dfb-bd6d1760b6b2https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Reports-Positive-Top-Line-Data-from-Exploratory-Phase-IIa-Trial-Of-IW-3718-in-Refractory-Gastroesophageal-Reflux-Disease/default.aspxWed, 04 Feb 2015 00:00:00 -05007e3be6c6-6bfa-42c8-9266-e19c0e9797a8https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-2014-Investor-Update-Call/default.aspxThu, 29 Jan 2015 00:00:00 -05007201e95d-d784-4a95-8870-94c858bb6703https://investor.ironwoodpharma.com/press-releases/press-release-details/2015/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20150105000000/default.aspxMon, 05 Jan 2015 00:00:00 -0500b8a2c732-edf1-46a9-b36e-0b7b2afaaab5https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-IIa-Clinical-Study-of-IW-9179-in-Diabetic-Gastroparesis/default.aspxTue, 09 Dec 2014 00:00:00 -0500db4d4e73-4af1-4336-8557-7664ee36d0d1https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Earns-15-Million-Milestone-from-Astellas-upon-Initiation-of-Enrollment-in-Linaclotide-Phase-III-IBS-C-Clinical-Trial-in-Japan/default.aspxThu, 20 Nov 2014 00:00:00 -0500d31dc282-c211-49c9-b442-cfb77ce3a42ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-2014-Healthcare-Conference/default.aspxWed, 05 Nov 2014 00:00:00 -050024a35f78-98a2-4cbe-8de3-34aca495aecdhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-III-Trial-of-72-mcg-Linaclotide-in-Adult-Patients-with-Chronic-Idiopathic-Constipation/default.aspxTue, 04 Nov 2014 00:00:00 -0500bfe24176-571c-43c3-998e-e75716781cedhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2014-Investor-Update/default.aspxTue, 04 Nov 2014 00:00:00 -05006f72d7e2-cdde-4d59-9cfc-620370b95c74https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Presents-IW-9179-Phase-IIa-Data-at-American-College-of-Gastroenterology-2014-Annual-Scientific-Meeting/default.aspxMon, 20 Oct 2014 00:00:00 -0400aec38328-d865-46a9-841c-6858ab05e45chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Announces-Initiation-of-Phase-II-Trial-of-Linaclotide-in-Adult-Patients-with-Opioid-Induced-Constipation/default.aspxThu, 16 Oct 2014 00:00:00 -04003d0061da-55ef-4020-840a-5a181fdceea8https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2014-Investor-Update-Call/default.aspxTue, 14 Oct 2014 00:00:00 -0400a6ff8a93-aa20-4b6c-9a10-a1c2967feba7https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-and-Actavis-to-Present-Linaclotide-Data-at-the-American-College-of-Gastroenterology-2014-Annual-Scientific-Meeting/default.aspxThu, 09 Oct 2014 00:00:00 -0400efc4c2f3-9944-4fc7-b107-9ecce9effcabhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference-20140903000000/default.aspxWed, 03 Sep 2014 00:00:00 -040082643c5d-ab3b-4977-926f-9e5dab5d2958https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Appoints-Two-New-Senior-Executives-to-Support-Continued-Growth-as-a-Leader-in-Gastroenterology/default.aspxTue, 02 Sep 2014 00:00:00 -0400f3916af2-aeb2-4ddd-88ca-26eb77b2852ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2014-Investor-Update/default.aspxMon, 04 Aug 2014 00:00:00 -0400a09c5ad2-8acc-4d1d-b10e-de146b086231https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2014-Investor-Update-Call/default.aspxMon, 07 Jul 2014 00:00:00 -0400f443f4b6-2251-40ce-bc98-83006964929fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Goldman-Sachs-Global-Healthcare-Conference/default.aspxThu, 05 Jun 2014 00:00:00 -0400d8df75fe-2e37-45cf-b55b-42f9ad088fcehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Appoints-Douglas-Williams-PhD-to-Board-of-Directors/default.aspxWed, 04 Jun 2014 00:00:00 -04004b45974b-74c8-430e-8ee7-031091cd6b1chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Bank-of-America-Merrill-Lynch-2014-Healthcare-Conference/default.aspxWed, 07 May 2014 00:00:00 -040054d31047-44f4-446f-a8a4-1ec1734b8667https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-and-Forest-to-Present-Linaclotide-Data-at-Digestive-Disease-Week-2014/default.aspxThu, 01 May 2014 00:00:00 -040063ac3871-5bab-415c-b526-bd9e0767d89ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-First-Quarter-2014-Investor-Update/default.aspxTue, 29 Apr 2014 00:00:00 -04006ecb0649-29ac-4871-8ff9-80ecff4661cfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-and-Forest-Launch-New-Direct-to-Consumer-Awareness-Campaign-For-LINZESS/default.aspxThu, 10 Apr 2014 00:00:00 -0400feb806d2-ab37-4102-a065-a4b878fda201https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2014-Investor-Update-Call/default.aspxTue, 08 Apr 2014 00:00:00 -0400cfa1137b-bf47-498e-b70b-dc635fd4ded2https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Initiates-Phase-II-Clinical-Study-of-IW-3718-in-Refractory-Gastroesophageal-Reflux-Disease/default.aspxTue, 18 Mar 2014 00:00:00 -0400ae4b0363-9f2e-404c-abe1-71149a607f80https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-34th-Annual-Health-Care-Conference/default.aspxMon, 24 Feb 2014 00:00:00 -0500a3885ae1-dfb5-4db2-a1c7-0d61b383030fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Announces-Exercise-of-Underwriters-Option-in-Public-Offering-of-Common-Stock/default.aspxThu, 13 Feb 2014 00:00:00 -0500cb93a62b-fca0-4e18-8c65-d3c1307dbf1chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Appoints-Julie-McHugh-to-Board-of-Directors/default.aspxWed, 12 Feb 2014 00:00:00 -05009408c77f-aa1b-4a37-9564-d9a6bc81aa43https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Prices-Public-Offering-of-Common-Stock/default.aspxTue, 11 Feb 2014 00:00:00 -050027fe2e0d-5481-4017-9883-4b1bafb74b4fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Receives-Notice-of-Allowance-for-Methods-of-Use-Formulation-Patent-Expected-to-Extend-LINZESS-Patent-Protection-Through-2031/default.aspxMon, 10 Feb 2014 00:00:00 -05005c4ec61c-e4c9-46ce-99dc-99e87a5c5ca1https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock/default.aspxMon, 10 Feb 2014 00:00:00 -05001f1cf640-ae4f-4b40-b93e-14d2f23fc444https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-Leerink-Global-Healthcare-Conference/default.aspxFri, 07 Feb 2014 00:00:00 -050079fa01ee-1f43-46c0-917d-833d017372fbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-2013-Investor-Update/default.aspxTue, 21 Jan 2014 00:00:00 -0500aab774b2-c0b4-4c69-82c8-fe0ec5e4d695https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-Announces-Alignment-of-Workforce-with-Priority-Growth-Platforms/default.aspxWed, 08 Jan 2014 00:00:00 -05002bb5dfaf-e140-4392-b43d-f672c98e41ffhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-2013-Investor-Update-Call/default.aspxTue, 07 Jan 2014 00:00:00 -0500913706e8-ee97-4f89-8efc-35a6d32a7a51https://investor.ironwoodpharma.com/press-releases/press-release-details/2014/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20140106000000/default.aspxMon, 06 Jan 2014 00:00:00 -0500160fb770-663c-470a-8916-ce9806f18d00https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Details-Strategy-to-Establish-Leading-Gastrointestinal-Therapeutics-Company/default.aspxThu, 12 Dec 2013 00:00:00 -050030ee97af-9b7a-4f7c-be35-a404801780a5https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Host-Investor-Day-on-December-12-2013/default.aspxThu, 21 Nov 2013 00:00:00 -0500017a29a9-bf03-4dfe-92c2-5a7654c6f095https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-2013-Healthcare-Conference/default.aspxWed, 06 Nov 2013 00:00:00 -05007a5f0fbd-8a94-4fe7-a0c9-dd2d29d0b704https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2013-Investor-Update/default.aspxTue, 22 Oct 2013 00:00:00 -04003138c30d-3aaf-4aa5-840a-6d56fbfb4250https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2013-Investor-Update-Call/default.aspxTue, 08 Oct 2013 00:00:00 -040024068235-c2f6-4ca4-820f-031739efdc4ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-and-AstraZeneca-Initiate-Linaclotide-Phase-III-Trial-in-China-for-Adults-with-IBS-C/default.aspxTue, 10 Sep 2013 00:00:00 -0400a7e4d5c5-7fc9-4671-b53f-d261ca7e3948https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference-20130903000000/default.aspxTue, 03 Sep 2013 00:00:00 -0400d8273301-50b6-4c7c-b998-24b38fed50cfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Appoints-Dr-Michael-Hall-as-Senior-Vice-President-of-Clinical-Development/default.aspxWed, 21 Aug 2013 00:00:00 -0400746eec52-576a-4561-bb6a-15e4c67e2ca1https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2013-Investor-Update/default.aspxTue, 23 Jul 2013 00:00:00 -04003c21f2ff-db2a-4aec-98a1-3f4d428aa30chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2013-Investor-Update-Call/default.aspxTue, 09 Jul 2013 00:00:00 -0400ca5608de-2b2c-4cf1-a337-e960f94cc781https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Constella-linaclotide-the-first-approved-prescription-therapy-in-a-new-class-of-treatments-for-adults-with-IBS-C-is-now-available-in-Europe/default.aspxThu, 13 Jun 2013 00:00:00 -04007fe4ea98-943b-4df7-a647-a181aa4b387fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Announces-Partial-Exercise-of-Underwriters-Option-in-Public-Offering-of-Common-Stock/default.aspxTue, 04 Jun 2013 00:00:00 -0400769a10b4-3478-4ff0-87b5-b755593eb1b9https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Prices-Public-Offering-of-Common-Stock-20130521000000/default.aspxTue, 21 May 2013 00:00:00 -040041398434-afe5-47ee-a90e-9fb2e29f49e5https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock-20130520000000/default.aspxMon, 20 May 2013 00:00:00 -0400286c0b70-5144-42f5-b92d-fa65aa16b804https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-and-Forest-to-Present-Linaclotide-Data-at-Digestive-Disease-Week-2013/default.aspxTue, 14 May 2013 00:00:00 -0400489f7b52-4ed3-4f95-bdaf-109b7b54f95fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Present-at-Bank-of-America-Merrill-Lynch-2013-Health-Care-Conference/default.aspxTue, 07 May 2013 00:00:00 -040037ba2752-d4c6-4eca-a31a-0d2b823fae03https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Provides-First-Quarter-2013-Investor-Update/default.aspxTue, 23 Apr 2013 00:00:00 -04009d8460d9-6ff8-483f-9975-debac996d5c4https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2013-Investor-Update-Call/default.aspxTue, 02 Apr 2013 00:00:00 -040072614944-a11f-4003-afdf-6c1e20a3d506https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Appoints-Edward-Owens-to-Board-of-Directors/default.aspxMon, 04 Mar 2013 00:00:00 -050006f69350-f3c8-46d0-8847-d93e72fb00ddhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-33rd-Annual-Health-Care-Conference/default.aspxMon, 25 Feb 2013 00:00:00 -05005647264b-ba7a-41d6-a796-9a5c9bbd4bb6https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Promotes-Dr-Mark-Currie-to-Senior-Vice-President-Chief-Scientific-Officer-and-President-of-RD/default.aspxMon, 11 Feb 2013 00:00:00 -0500efc63a06-506c-45ce-8eff-8344fb944e8ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-2012-Investor-Update/default.aspxTue, 15 Jan 2013 00:00:00 -050060af73ed-58ab-43b7-b507-691cfbf77ce7https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-2012-Investor-Update-Call/default.aspxThu, 10 Jan 2013 00:00:00 -0500c5d121df-9105-423b-a190-10991e4353d7https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Completes-175-Million-Debt-Offering/default.aspxFri, 04 Jan 2013 00:00:00 -0500feaf347b-cb93-4156-8dec-13a172adfd89https://investor.ironwoodpharma.com/press-releases/press-release-details/2013/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20130102000000/default.aspxWed, 02 Jan 2013 00:00:00 -0500b2f7f6e5-584d-4fcb-ab20-50c8611ed845https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-Forest-Announce-US-Availability-of-LINZESS-Linaclotide/default.aspxMon, 17 Dec 2012 00:00:00 -0500b04fe67f-1921-4361-9824-b14256ec5edbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Protagonist-and-Ironwood-Expand-Peptide-Drug-Discovery-Collaboration/default.aspxThu, 06 Dec 2012 00:00:00 -0500028517c3-0cb8-4568-85e1-977b3e3cb01bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Constella-linaclotide-Approved-in-Europe-for-the-Treatment-of-Irritable-Bowel-Syndrome-with-Constipation-IBS-C-in-Adults/default.aspxWed, 28 Nov 2012 00:00:00 -050018b3b351-297f-49bc-8233-ee16b953ad60https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-the-Credit-Suisse-2012-Healthcare-Conference/default.aspxFri, 09 Nov 2012 00:00:00 -0500ad246d07-19aa-4d00-9afa-74f57906573dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Host-Webinar-on-Accounting-Treatment-for-LINZESS-Linaclotide/default.aspxThu, 01 Nov 2012 00:00:00 -0400dbb068d7-43b0-43c9-9e32-5f91861a2221https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-AstraZeneca-Announce-Linaclotide-Collaboration-for-China/default.aspxTue, 23 Oct 2012 00:00:00 -0400062deadb-6f4d-41fa-8a26-61861d350975https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2012-Investor-Update/default.aspxTue, 16 Oct 2012 00:00:00 -04006020a97c-bf87-46ad-88fa-e178dbc4cf47https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2012-Investor-Update-Call/default.aspxTue, 09 Oct 2012 00:00:00 -0400af29004c-b787-4a6c-a67a-ed3414705e33https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Linaclotide-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-IBS-C/default.aspxFri, 21 Sep 2012 00:00:00 -04005d96b278-e655-4294-9e90-751d4b7cda74https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-the-UBS-Global-Life-Sciences-Conference/default.aspxWed, 12 Sep 2012 00:00:00 -0400e0e1e01a-1120-415b-a4d8-db1957a3cfe7https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-the-Morgan-Stanley-Global-Healthcare-Conference/default.aspxThu, 06 Sep 2012 00:00:00 -04006a1c95fe-138d-4b05-b4d0-c5a17770ef07https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-Forest-to-Host-Conference-Call-to-Discuss-FDA-Approval-of-LINZESS-Linaclotide-for-the-Treatment-of-Irritable-Bowel-Syndrome-with-Constipation-and-Chronic-Idiopathic-Constipation/default.aspxThu, 30 Aug 2012 00:00:00 -0400fdeb21bd-07a0-4ff5-9a36-c8fd8b9c35e3https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-Forest-Announce-FDA-Approval-of-LINZESS-Linaclotide-for-the-Treatment-of-Irritable-Bowel-Syndrome-with-Constipation-and-Chronic-Idiopathic-Constipation/default.aspxThu, 30 Aug 2012 00:00:00 -04007f6b8fb7-5d98-4b2f-a42a-3d3a68a8ce5ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2012-Investor-Update/default.aspxTue, 17 Jul 2012 00:00:00 -040090fd3cf7-d284-4a0b-9e97-c639a8eb69dchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2012-Investor-Update-Call/default.aspxTue, 10 Jul 2012 00:00:00 -0400523282c7-8514-41bf-9c67-c9939c69ae8ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences/default.aspxTue, 29 May 2012 00:00:00 -040088e44a27-ea57-4d63-b1bf-9685de0223c6https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-Forest-to-Present-17-Linaclotide-Related-Abstracts-at-Digestive-Disease-Week-2012/default.aspxMon, 14 May 2012 00:00:00 -04009cedef68-0e1b-48b1-8c0d-877b75dbaa09https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-Bank-of-America-Merrill-Lynch-2012-Health-Care-Conference/default.aspxTue, 08 May 2012 00:00:00 -04009d93f77a-3453-4dfe-8838-e91f9fb12fe9https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Provides-First-Quarter-2012-Investor-Update/default.aspxTue, 01 May 2012 00:00:00 -04006aff884b-2685-4414-9aea-43af8488fc1bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2012-Investor-Update-Call/default.aspxTue, 24 Apr 2012 00:00:00 -04003dadf5a7-4b98-4151-88bf-10c61a0e6323https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-and-Forest-Announce-FDA-Has-Extended-the-Review-Period-for-Linaclotide-to-September-2012/default.aspxMon, 23 Apr 2012 00:00:00 -040001821668-da1f-49d3-aa4c-cc9d9b1463dfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-2011-Investor-Update/default.aspxTue, 28 Feb 2012 00:00:00 -050027e9dafc-6503-45a8-a12a-411b93a701a0https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-Cowen-and-Company-Annual-Health-Care-Conference/default.aspxMon, 27 Feb 2012 00:00:00 -050061c093a0-ced3-4ce7-9252-644d076c196ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-2011-Investor-Update-Call/default.aspxTue, 21 Feb 2012 00:00:00 -05008cbc350b-7323-4994-836d-b7d847f7c68dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Announces-Exercise-of-Over-Allotment-Option-in-Public-Offering-of-Common-Stock/default.aspxMon, 13 Feb 2012 00:00:00 -0500527dc543-120d-4d55-b34e-888d53450f9dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Prices-Public-Offering-of-Common-Stock-20120209000000/default.aspxThu, 09 Feb 2012 00:00:00 -050089e803fb-5396-4678-abf0-c7c8ace34a60https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock-20120208000000/default.aspxWed, 08 Feb 2012 00:00:00 -0500a70c0b30-3e40-424f-8cbf-f2b2788e8e85https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Announces-FDA-Advisory-Committee-Meeting-Will-Not-Be-Scheduled-in-Connection-with-New-Drug-Application-for-Linaclotide/default.aspxWed, 08 Feb 2012 00:00:00 -05005d22c2bd-d385-4c1e-a575-fae2d25e8e99https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-and-Bionomics-Announce-Collaboration-Research-and-License-Agreement/default.aspxWed, 04 Jan 2012 00:00:00 -0500fc099b8f-3cef-42e3-8666-4e2a1ee7b202https://investor.ironwoodpharma.com/press-releases/press-release-details/2012/Ironwood-Pharmaceuticals-to-Present-at-JP-Morgan-Healthcare-Conference-20120103000000/default.aspxTue, 03 Jan 2012 00:00:00 -0500fa1b414d-5e2b-403d-a543-70b67549a38ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2011-Investor-Update/default.aspxMon, 07 Nov 2011 00:00:00 -050005253dd7-4eeb-4d2f-8a8b-5479d95dcd8bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Present-at-Credit-Suisse-2011-Healthcare-Conference/default.aspxWed, 02 Nov 2011 00:00:00 -0400e0a951d0-0b37-47e0-8ef0-4b1e320c254fhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2011-Investor-Update-Call/default.aspxMon, 31 Oct 2011 00:00:00 -0400c0540a54-328e-4973-a1fc-c32cc2d8519ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-and-Forest-to-Present-Linaclotide-Results-from-Phase-2B-and-Phase-3-Trials-in-Patients-with-Irritable-Bowel-Syndrome-with-Constipation-or-Chronic-Constipation/default.aspxThu, 27 Oct 2011 00:00:00 -04005f39ecbe-a6af-40c5-b297-bb5ee65644a0https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-and-Forest-Announce-Linaclotide-New-Drug-Application-for-the-Treatment-of-Irritable-Bowel-Syndrome-with-Constipation-and-Chronic-Constipation-Accepted-for-FDA-Review/default.aspxMon, 24 Oct 2011 00:00:00 -0400f9a8a617-19c1-4e66-abeb-4dd5ddd2e00ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Announces-Linaclotide-European-Regulatory-Submission-for-the-Treatment-of-Irritable-Bowel-Syndrome-with-Constipation/default.aspxThu, 29 Sep 2011 00:00:00 -0400de03858c-17bf-45fe-b464-24e19bf57b9ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Present-at-Jefferies-2011-Global-Healthcare-Conference/default.aspxWed, 21 Sep 2011 00:00:00 -0400fed1df0b-d3a4-4230-ae21-6deed79a0f82https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Present-at-Morgan-Stanley-Global-Healthcare-Conference-20110906000000/default.aspxTue, 06 Sep 2011 00:00:00 -0400c832cfa9-05f0-4d5b-acc5-afef83801e8chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2011-Investor-Update/default.aspxThu, 11 Aug 2011 00:00:00 -0400ab089816-a555-44fb-a06b-bcc9d66d86d2https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Present-at-Wedbush-Securities-2011-Life-Sciences-Management-Access-Conference/default.aspxWed, 10 Aug 2011 00:00:00 -04001c3b2095-a4a3-489f-83ef-c38efe83fbd2https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-and-Forest-Announce-Submission-of-New-Drug-Application-for-Linaclotide-for-the-Treatment-of-Irritable-Bowel-Syndrome-With-Constipation-and-Chronic-Constipation/default.aspxTue, 09 Aug 2011 00:00:00 -04009e6dca6c-397d-48bb-8995-f7064858b786https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2011-Investor-Update-Call/default.aspxMon, 08 Aug 2011 00:00:00 -0400e2807684-c1ec-4bdb-9d5d-3168f671bf38https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-and-Depomed-Announce-Collaboration-Research-and-License-Agreement/default.aspxWed, 27 Jul 2011 00:00:00 -0400a954c546-7769-461c-9997-70f6e36a948dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentations-at-Jefferies-Global-Healthcare-Conference-and-Goldman-Sachs-Annual-Global-Healthcare-Conference/default.aspxTue, 31 May 2011 00:00:00 -04008adf2f57-1268-4648-a3a7-286cc4c01627https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Provides-First-Quarter-2011-Investor-Update/default.aspxThu, 12 May 2011 00:00:00 -0400ea05b1b1-ff76-4985-83bc-4f848d1d6269https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Host-First-Quarter-2011-Investor-Update-Call/default.aspxThu, 05 May 2011 00:00:00 -0400b3f91e90-e695-455c-9262-01db7c0250b1https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-Bank-of-America-Merrill-Lynch-2011-Health-Care-Conference/default.aspxWed, 04 May 2011 00:00:00 -04005c9bdfa1-e6da-436f-bc29-33835c8bb8cfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-Cowen-and-Company-Annual-Health-Care-Conference/default.aspxThu, 03 Mar 2011 00:00:00 -0500e3562bc0-5b24-4e98-84de-83f66f3b088ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Provides-Fourth-Quarter-2010-Investor-Update/default.aspxThu, 03 Mar 2011 00:00:00 -050026bf56c8-8c35-40d9-91c0-a3160128012dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-2010-Investor-Update-Call/default.aspxMon, 28 Feb 2011 00:00:00 -050065e3c802-e85f-4221-98b9-bc131d882246https://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-and-Protagonist-Establish-Collaboration-for-Peptide-Drug-Discovery-and-Development/default.aspxTue, 18 Jan 2011 00:00:00 -050070e3aef5-ec2d-43bf-aa67-90516f9b305dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2011/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-JP-Morgan-Healthcare-Conference/default.aspxThu, 06 Jan 2011 00:00:00 -0500223ca2c4-f4f0-4aa4-b224-ebc9ccc7ed4chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-Credit-Suisse-2010-Healthcare-Conference/default.aspxFri, 05 Nov 2010 00:00:00 -04004d5e4a57-e976-4e57-b4f1-b2f8f4fbd57ehttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Provides-Third-Quarter-2010-Investor-Update/default.aspxThu, 04 Nov 2010 00:00:00 -0400ca7a8c66-02e5-4f6e-b604-4dbca1160f99https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-and-Forest-Announce-Positive-Linaclotide-Results-from-Second-Phase-3-Trial-in-Patients-with-Irritable-Bowel-Syndrome-with-Constipation/default.aspxMon, 01 Nov 2010 00:00:00 -0400bab24eb0-4b1c-46f9-acd4-9e4d9f98e8cbhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Conference-Call-to-Discuss-Positive-Linaclotide-Phase-3-IBS-C-Results/default.aspxMon, 01 Nov 2010 00:00:00 -0400c4d151d9-a10c-46df-b446-cfdcb717a3a9https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Almirall-and-Ironwood-Announce-Positive-Results-from-the-Second-Phase-3-Trial-of-Linaclotide-in-Patients-with-Irritable-Bowel-Syndrome-with-Constipation/default.aspxMon, 01 Nov 2010 00:00:00 -04001558d71e-e587-4bb2-92fe-214db7cd0546https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-and-Forest-Announce-Positive-Linaclotide-Results-from-Phase-3-Trial-in-Patients-with-Irritable-Bowel-Syndrome-with-Constipation/default.aspxMon, 13 Sep 2010 00:00:00 -04004978b26a-2bf7-4ae7-a14f-84859661dc14https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Almirall-and-Ironwood-Announce-Positive-Results-from-a-Phase-3-Trial-with-Linaclotide-in-Patients-with-Irritable-Bowel-Syndrome-with-Constipation/default.aspxMon, 13 Sep 2010 00:00:00 -0400919f73ee-ca94-4fb6-8bda-f95e3fb5228dhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Conference-Call-to-Discuss-Positive-Linaclotide-Phase-3-IBS-C-Results-20100913000000/default.aspxMon, 13 Sep 2010 00:00:00 -0400e314edc9-920f-4794-9938-67bbb45e58dchttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-Morgan-Stanley-Global-Healthcare-Conference/default.aspxThu, 09 Sep 2010 00:00:00 -0400e2934d5a-2cce-4ed6-a12e-0f5ef7d86e9ahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Provides-Second-Quarter-2010-Investor-Update/default.aspxThu, 05 Aug 2010 00:00:00 -040030598fdb-069d-4556-9c51-ab3f75340438https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Second-Quarter-2010-Investor-Update-Call/default.aspxMon, 02 Aug 2010 00:00:00 -04006f77e638-de45-415d-8b0b-2034f15073b9https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Upcoming-Presentation-at-Wedbush-Life-Sciences-MAC-Best-Ideas-2010/default.aspxWed, 28 Jul 2010 00:00:00 -0400ef3fca2e-a790-4011-a441-7dad67f165f3https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-Participation-in-JP-Morgan-Biotech-CEOCFO-Conference-Call/default.aspxWed, 26 May 2010 00:00:00 -0400c5e6d58a-32f0-4d3c-b96f-f41ba33a3daahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Provides-First-Quarter-2010-Investor-Update/default.aspxTue, 11 May 2010 00:00:00 -04001362b127-abf9-4815-95e3-81ed85cfcfb1https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Announces-First-Quarter-2010-Investor-Update-Call-and-Upcoming-Presentation-at-Bank-of-America-Merrill-Lynch-2010-Health-Care-Conference/default.aspxFri, 07 May 2010 00:00:00 -04007256645d-6dbb-423d-bb28-69367ae2ea79https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Ironwood-Pharmaceuticals-Files-Annual-Report-on-Form-10-K/default.aspxTue, 30 Mar 2010 00:00:00 -04006aa76d64-2d61-4f5a-b965-27aeb9477600https://investor.ironwoodpharma.com/press-releases/press-release-details/2010/Underwriters-Exercise-Over-Allotment-Option-for-Ironwood-Pharmaceuticals-Initial-Public-Offering/default.aspxTue, 16 Feb 2010 00:00:00 -0500e8230020-7e99-4e55-b7ca-4165f3a8927bhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-Pharmaceuticals-Files-Registration-Statement-for-Initial-Public-Offering/default.aspxFri, 20 Nov 2009 00:00:00 -0500d9159218-2b1e-4284-9c2d-c9cdc155d4fahttps://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-and-Astellas-Announce-Japan-Licensing-Agreement-for-Linaclotide/default.aspxTue, 10 Nov 2009 00:00:00 -050004cfe00d-cc48-4cfe-9601-213184b801dfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-and-Forest-Announce-Positive-Linaclotide-Results-from-Two-Pivotal-Phase-3-Trials-In-Patients-with-Chronic-Constipation/default.aspxMon, 02 Nov 2009 00:00:00 -0500583b0bbb-a181-4b36-a7ad-ca7554675ee3https://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Marsha-Fanucci-Joins-Ironwood-Board-of-Directors/default.aspxTue, 27 Oct 2009 00:00:00 -0400870681a2-712d-4fa6-860e-5e4c10c4f229https://investor.ironwoodpharma.com/press-releases/press-release-details/2009/David-Ebersman-Joins-Ironwood-Board-of-Directors/default.aspxMon, 14 Sep 2009 00:00:00 -0400da00f6da-bfd1-4113-a040-ffc61318b378https://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-Appoints-Thomas-McCourt-as-Chief-Commercial-Officer-and-Senior-Vice-President-of-Marketing-and-Sales/default.aspxMon, 14 Sep 2009 00:00:00 -040057998a73-2707-4d22-8be0-e4f7e7587e37https://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-And-Forest-Present-Additional-Positive-Phase-2b-Study-Results-For-Linaclotide-In-Patients-With-Irritable-Bowel-Syndrome-With-Constipation/default.aspxSun, 31 May 2009 00:00:00 -040048f9f4df-4952-44c3-b711-96f00e4c867chttps://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-And-Forest-To-Present-Additional-Phase-2b-Data-For-Novel-Gastrointestinal-Agent-Linaclotide/default.aspxTue, 12 May 2009 00:00:00 -0400f3998eb7-9a37-4ca7-903d-274a25e9f3cfhttps://investor.ironwoodpharma.com/press-releases/press-release-details/2009/Ironwood-Announces-Linaclotide-European-Licensing-Agreement-With-Almirall/default.aspxMon, 04 May 2009 00:00:00 -040015dfe845-f81a-407f-9c9a-718623d2dccbhttps://investor.ironwoodpharma.com/files/doc_news/archive/ac7b20aa-369a-45a6-bfe3-771abd9995dc.pdfTue, 21 Oct 2008 00:00:00 -04000d9c005f-b8a3-4bf8-8d09-a883e840ec59https://investor.ironwoodpharma.com/files/doc_news/archive/6e3a3ef2-a4ff-4508-b89c-612b88f71a4e.pdfTue, 07 Oct 2008 00:00:00 -0400e5b997c9-9d50-4f39-9486-36f8b97017e3https://investor.ironwoodpharma.com/files/doc_news/archive/63e9689e-91d0-4cbd-af94-dbe8e8e604c6.pdfMon, 06 Oct 2008 00:00:00 -04005fada806-adc0-4690-8574-037261f6eb1dhttps://investor.ironwoodpharma.com/files/doc_news/archive/041dce91-e5f3-48b2-9056-01078a80dddd.pdfWed, 01 Oct 2008 00:00:00 -04003bb2a4c3-0990-4a30-ba0e-446acf786073https://investor.ironwoodpharma.com/files/doc_news/archive/9f9d25fc-8d2e-470b-9126-8cf0e73f81a0.pdfTue, 23 Sep 2008 00:00:00 -0400b6fe7c7e-9fba-4c07-89bc-59183b9e313ehttps://investor.ironwoodpharma.com/files/doc_news/archive/7065f7c2-86ce-45e6-84d3-711631e69aa5.pdfTue, 20 May 2008 00:00:00 -04008a58d47b-36a8-4e66-bd1c-d32c5583ca14https://investor.ironwoodpharma.com/files/doc_news/archive/d6e08fdc-77d1-44d9-8197-3ff4a45d0e77.pdfMon, 07 Apr 2008 00:00:00 -0400e01efd5f-6d00-4e63-92a6-00be6d469012https://investor.ironwoodpharma.com/files/doc_news/archive/aa59cac7-ee72-46c1-a384-77b9ec20fdc5.pdfMon, 31 Mar 2008 00:00:00 -0400a12c4630-76cc-44e8-bd26-379b2ef54dd2https://investor.ironwoodpharma.com/files/doc_news/archive/a4881832-4d25-44bd-bf97-5d0abb87d72e.pdfTue, 04 Mar 2008 00:00:00 -0500